J 2017

Black Phosphorus Nanoparticles Potentiate the Anticancer Effect of Oxaliplatin in Ovarian Cancer Cell Line

FOJTŮ, Michaela, Xinyi CHIA, Zdeněk SOFER, Michal MASAŘÍK, Martin PUMERA et. al.

Basic information

Original name

Black Phosphorus Nanoparticles Potentiate the Anticancer Effect of Oxaliplatin in Ovarian Cancer Cell Line

Authors

FOJTŮ, Michaela (203 Czech Republic, belonging to the institution), Xinyi CHIA (702 Singapore), Zdeněk SOFER (203 Czech Republic), Michal MASAŘÍK (203 Czech Republic, guarantor, belonging to the institution) and Martin PUMERA (702 Singapore)

Edition

Advanced Functional Materials, Wrinheim, Wiley-VCH Verlag, 2017, 1616-301X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10400 1.4 Chemical sciences

Country of publisher

Germany

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 13.325

RIV identification code

RIV/00216224:14110/17:00095042

Organization unit

Faculty of Medicine

UT WoS

000412319400006

Keywords in English

black phosphorus; drug delivery; nanoparticles ovarian; cancer oxaliplatin

Tags

Tags

International impact, Reviewed
Změněno: 20/3/2018 17:41, Soňa Böhmová

Abstract

V originále

During the past few years, growing attention has been paid to black phosphorus (BP) and its unique optical, electrical, and catalytic properties. Furthermore, BP has proven to be biocompatible and biodegradable; qualities that present new opportunities for its utilization in the field of life sciences. However, despite all its suitable properties and applicability, its utilization in biomedicine is still in its infancy. This study reports on the synthesis of black phosphorus nanoparticles (BP NPs) and exploration of thier applicability in targeted drug delivery. BP NPs are loaded with platinum agents—cisplatin and oxaliplatin—and subjected to in vitro evaluation of targeted drug delivery. The BP NPs are not only able to load the investigated platinum derivatives on their surfaces, but also to transfer the therapeutic cargo to target specific tissue and to combine their effect with oxaliplatin, which leads to further potentiation of the anticancer effect.

Links

GA16-05961S, research and development project
Name: Pokročilé nosiče platinových léčiv
Investor: Czech Science Foundation
MUNI/A/1355/2016, interní kód MU
Name: Kardiovaskulární systém očima molekulární fyziologie
Investor: Masaryk University, Category A
ROZV/24/LF/2016, interní kód MU
Name: LF - Příspěvek IP 2016
Investor: Ministry of Education, Youth and Sports of the CR